New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases

Marchais-Oberwinkler S, Sandrine Marchais-Oberwinkler, Marie Wetzel, Wetzel M, Ziegler E, Erika Ziegler, Patricia Kruchten, Kruchten P, Werth R, Ruth Werth, Claudia Henn, Henn C, Rolf W. Hartmann, Hartmann RW, Martin Frotscher, Frotscher M
Journal of medicinal chemistry · 2011 · vol. 54(2) , pp. 534–47 · doi:10.1021/jm1009082 · PMID:21189020
Lab / animal OA: green public-domain-us
🔓 Open OA copy Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-23 ⓘ

Researchers synthesized novel hydroxyphenylnaphthol steroidomimetics, with methanesulfonamide 15 showing potent, selective inhibition of 17β-HSD1, good cellular activity, and oral availability in rats.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-23 · read from full text ⓘ

The paper reports new hydroxyphenylnaphthol steroidomimetic compounds designed as selective inhibitors of human 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), using ligand displacement of radiolabeled estradiol/estrone substrates in human placental enzyme preparations and functional assessment in the T47D breast cancer cell line. The compounds showed 17β-HSD1 inhibitory activity in the low nanomolar to submicromolar range across multiple in vitro assays. The paper also notes off-target inhibition against several cytochrome P450 enzymes (e.g., CYP1A2, CYP2C9, CYP2C19, CYP3A4, etc.), indicating potential liability for selectivity. This paper is centrally about endometriosis—specifically, it targets estrogen-dependent biology via 17β-HSD1 inhibition, an estrogen-regulating pathway relevant to endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) is a novel and attractive approach to reduce the local levels of the active estrogen 17β-estradiol in patients with estrogen-dependent diseases like breast cancer or endometriosis. With the aim of optimizing the biological profile of 17β-HSD1 inhibitors from the hydroxyphenylnaphthol class, structural optimizations were performed at the 1-position of the naphthalene by introduction of different heteroaromatic rings as well as substituted phenyl groups. In the latter class of compounds, which were synthesized applying Suzuki-cross coupling, the 3-methanesulfonamide 15 turned out to be a highly potent 17β-HSD1 inhibitor (IC(50) = 15 nM in a cell-free assay). It was also very active in the cellular assay (T47D cells, IC(50) = 71 nM) and selective toward 17β-HSD2 and the estrogen receptors α and β. It showed a good membrane permeation and metabolic stability and was orally available in the rat.
Full text 7,271 characters · extracted from oa-html · click to expand
Report error Found 54 Enz. Inhib. hit(s) with all data for entry = 50032861 Affinity DataIC50: 10nMAssay Description:Inhibition of human CYP1A2More data for this Ligand-Target Pair Affinity DataIC50: 10nMAssay Description:Inhibition of human CYP2D6More data for this Ligand-Target Pair Affinity DataIC50: 15nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 20nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 26nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 33nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 36nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 40nMAssay Description:Inhibition of human CYP3A4More data for this Ligand-Target Pair Affinity DataIC50: 50nMAssay Description:Inhibition of human CYP3A4More data for this Ligand-Target Pair Affinity DataIC50: 53nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 64nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 70nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 71nMAssay Description:Displacement of [3H]E1 from 17beta-HSD1 in human T47D cells after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 115nMAssay Description:Displacement of [3H]E1 from 17beta-HSD1 in human T47D cells after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 116nMAssay Description:Displacement of [3H]E1 from human placental 17beta-HSD1 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 150nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair Affinity DataIC50: 165nMAssay Description:Displacement of [3H]E1 from 17beta-HSD1 in human T47D cells after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 220nMAssay Description:Inhibition of human CYP3A4More data for this Ligand-Target Pair Affinity DataIC50: 229nMAssay Description:Displacement of [3H]E1 from 17beta-HSD1 in human T47D cells after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 250nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair Affinity DataIC50: 270nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair Affinity DataIC50: 281nMAssay Description:Displacement of [3H]E1 from 17beta-HSD1 in human T47D cells after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 403nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 527nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 530nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 540nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 670nMAssay Description:Displacement of [3H]E1 from 17beta-HSD1 in human T47D cells after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 680nMAssay Description:Inhibition of human CYP2C19More data for this Ligand-Target Pair Affinity DataIC50: 880nMAssay Description:Inhibition of human CYP2C19More data for this Ligand-Target Pair Affinity DataIC50: 959nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 1.07E+3nMAssay Description:Inhibition of human CYP3A4More data for this Ligand-Target Pair Affinity DataIC50: 1.16E+3nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 1.25E+3nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair Affinity DataIC50: 1.41E+3nMAssay Description:Inhibition of human CYP2C19More data for this Ligand-Target Pair Affinity DataIC50: 1.64E+3nMAssay Description:Inhibition of human CYP2C9More data for this Ligand-Target Pair Affinity DataIC50: 1.76E+3nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 2.77E+3nMAssay Description:Inhibition of human CYP3A4More data for this Ligand-Target Pair Affinity DataIC50: 3.04E+3nMAssay Description:Inhibition of human CYP1A2More data for this Ligand-Target Pair Affinity DataIC50: 3.04E+3nMAssay Description:Inhibition of human CYP2C19More data for this Ligand-Target Pair Affinity DataIC50: 3.34E+3nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 5.34E+3nMAssay Description:Inhibition of human CYP2B6More data for this Ligand-Target Pair Affinity DataIC50: 5.64E+3nMAssay Description:Displacement of [3H]E2 from human placental 17beta-HSD2 after 10 mins by fluid scintillation countingMore data for this Ligand-Target Pair Affinity DataIC50: 6.03E+3nMAssay Description:Inhibition of human CYP2C19More data for this Ligand-Target Pair Affinity DataIC50: 6.96E+3nMAssay Description:Inhibition of human CYP2B6More data for this Ligand-Target Pair Affinity DataIC50: 7.16E+3nMAssay Description:Inhibition of human CYP1A2More data for this Ligand-Target Pair Affinity DataIC50: 7.96E+3nMAssay Description:Inhibition of human CYP2B6More data for this Ligand-Target Pair Affinity DataIC50: 1.04E+4nMAssay Description:Inhibition of human CYP2B6More data for this Ligand-Target Pair Affinity DataIC50: 1.05E+4nMAssay Description:Inhibition of human CYP1A2More data for this Ligand-Target Pair Affinity DataIC50: 1.19E+4nMAssay Description:Inhibition of human CYP2B6More data for this Ligand-Target Pair Affinity DataIC50: 1.55E+4nMAssay Description:Inhibition of human CYP2D6More data for this Ligand-Target Pair

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

17-Hydroxysteroid Dehydrogenases Estrogens Naphthols Phenols Steroids 17-Hydroxysteroid Dehydrogenases 17-Hydroxysteroid Dehydrogenases Administration, Oral Administration, Oral Animals Animals Biological Availability Biological Availability Cell-Free System Cell-Free System Cell Line, Tumor Cell Line, Tumor Cell Membrane Permeability Cell Membrane Permeability Estrogen Receptor alpha

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-11-13T07:00:47.251693+00:00
pubmed
last seen: 2026-10-08T21:08:28.697392+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine